Perindopril arginine + amlodipine for the treatment of hypertension in the USA

Bibliography

• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics–2015 update. a report from the American Heart Association. Circulation 2015;131:e1-295
   PubMed Web of Science ®Google Scholar
• Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of diseases and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2224-60
   PubMed Web of Science ®Google Scholar
• Yusuf S, Rangarajan S, Teo K, et al. for the Prospective Urban Rural Epidemiologic (PURE) Investigators. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med 2014;371:818-27
   PubMed Web of Science ®Google Scholar
• Falaschetti E, Mindell J, Knott C, Poulter N. Hypertension management in England: A serial cross-sectional study from 1994 to 2011. Lancet 2014;383:1912-19
   PubMed Web of Science ®Google Scholar
• Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, medium-, and low-income countries. JAMA 2013;310:959-68
   PubMed Web of Science ®Google Scholar
• World Health Organisation. A global brief on hypertension: Silent killer, global public health crisis. Geneva, Switzerland, 2013. p. 40. Available from: www.apps.who.int/iris/bitstream/10665/79059/1/WHO_DCO_WHD_2013.2_eng.pdf [Last accessed 20 February 2015]
   Google Scholar
• James PA, Oparil S, Carter BL, et al. Evidence-based guidelines for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-20
   PubMed Web of Science ®Google Scholar
• Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the american society of hypertension and the international society of hypertension. J Clin Hypertens (Greenwich) 2014;16:14-26
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the management of arterial hypertension. J Hypertens 2013;31:1925-38
   PubMed Web of Science ®Google Scholar
• Higgins B, Williams B, Williams H, et al. for The Guideline Development Groups, National Colllaborating Centres, and NICE Project Team. United Kingdom National Health Service: National Institute for Health and Clinical Excellence. NICE clinical guideline 127: Hypertension: Clinical management of primary hypertension in adults. Available from: www.nice.org.uk/CG127; First accessed 24 Aug 2011; most recent access 03 Mar 2015
   Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. National High Blood Pressure Education Program Coordinating Committee. Hypertension 2003;42:1206-52
   PubMed Web of Science ®Google Scholar
• Gupta AK, Arshad S, Poulter NS. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: A meta-analysis. Hypertension 2010;55:399-407
   PubMed Web of Science ®Google Scholar
• de Cates AN, Farr MRB, Wright N, et al. Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev 2014;4:CD009868
   PubMedGoogle Scholar
• Todd PA, Fitton A. Perindopril: A review of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 1991;42:90-114
   PubMed Web of Science ®Google Scholar
• Ennezat PV, Berlowitz M, Sonnenblick EH, Le Jemtel TH. Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Curr Cardiol Rep 2000;2:258-62
   PubMedGoogle Scholar
• Australian Government Department of Health and Ageing. Pharmaceutical benefits scheme for health professionals. 2008. Available from: www.pbs.gov.au [Last accessed on 05 Mar 2015]
   Google Scholar
• PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41
   PubMed Web of Science ®Google Scholar
• Fox KM; the EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (The EUROPA study). Lancet 2003;362:782-8
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005;366:895-906
   PubMed Web of Science ®Google Scholar
• Patel A; the ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 2007;370:829-40
   PubMed Web of Science ®Google Scholar
• Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-98
   PubMed Web of Science ®Google Scholar
• Elliott WJ. Rationale for a single-pill combination of perindopril arginine and amlodipine besylate. J Am Soc Hypertens 2015;9:257-65
   PubMed Web of Science ®Google Scholar
• Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: Is it a wise choice? Lancet 2004;364:1684-9
   PubMed Web of Science ®Google Scholar
• Psaty BM, Weiss NS, Furberg CD. Recent trials in hypertension: Compelling science or commercial speech? JAMA 2006;295:1704-6
   PubMed Web of Science ®Google Scholar
• Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on progression of atherosclerosis and the occurrence of clinical events. Circulation 2000;102:1503-10
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Libby P, et al. for the CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT Study: A randomized controlled trial. JAMA 2004;292:2217-25
   PubMed Web of Science ®Google Scholar
• The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97
   PubMed Web of Science ®Google Scholar
• Tatti P, Pahor M, Byington RP, et al. Outcome results of the fosinopril amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:1779-80
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen S, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004;363:2022-31
   PubMed Web of Science ®Google Scholar
• Ogihara T, Nakao K, Fukui T, et al. for the Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension 2008;51:393-8
   PubMed Web of Science ®Google Scholar
• Narumi H, Takano H, Shindo S, et al. for the Valsartan Amlodipine Randomized Trial Investigators. Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertens Res 2011;34:62-9
   PubMed Web of Science ®Google Scholar
• Muramatsu T, Matsushita K, Yamashita K, et al. for the Nagoya Heart Study Investigators. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: Nagoya Heart Study. Hypertension 2012;59:580-6
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. Collaborative Study Group. N Engl J Med 2001;345:851-60
   PubMed Web of Science ®Google Scholar
• Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Irbesartan Diabetic Nephropathy Trial Collaborative Study Group. Ann Intern Med 2003;138:542-9
   PubMed Web of Science ®Google Scholar
• Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. African American Study of Kidney Disease and Hypertension (AASK) study group. JAMA 2001;285:2719-28
   PubMed Web of Science ®Google Scholar
• Norris K, Bourgoigne J, Gassman J, et al. for the AASK Study Group. Cardiovascular outcomes in the african american study of kidney disease and hypertension (AASK) Trial. Am J Kidney Dis 2006;48:739-51
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL, et al. for the ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28
   PubMed Web of Science ®Google Scholar
• Elliott WJ, Basu S, Meyer PM. Network meta-analysis of heart failure prevention by antihypertensive drugs [Letter]. Arch Intern Med 2011;171:472-3
   PubMed Web of Science ®Google Scholar
• Meurin P. The ASCOT trial: clarifying the role of ACE inhibition in the reduction of cardiovascular events in patients with hypertension. Am J Cardiovasc Drugs 2006;6:327-34
   PubMedGoogle Scholar
• Bahl VK, Jadhav UM, Thacker HP. Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: Results from the STRONG prospective, observational, multicenter study. Am J Cardiovasc Drugs 2009;9:135-42
   PubMed Web of Science ®Google Scholar
• Hatala R, Pella D, Hatalová K, Sidlo R. Optimization of blood pressure treatment with fixed-combination perindopril/amlodipine in patients with arterial hypertension. Clin Drug Invest 2012;32:603-12
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ly C, Yannoutsos A, et al. Effect of a fixed-dose combination of perindopril and amlodipine on blood pressure control in 6256 patients with not-at-goal hypertension: The AVANT’AGE study. J Am Soc Hypertens 2013;7:163-9
   PubMed Web of Science ®Google Scholar
• Kobalava ZhD, Kotovskaia IuV, Luk’ianova EA. Combined therapy of arterial hypertension with the fixed combination of perindopril arginine/amlodipine in real clinical practice: The organization and the main results of the program CONSTANTA [in Russian]. Kardiologiia 2013;53:25-34
   PubMed Web of Science ®Google Scholar
• Bansal S, Chauhan DK, Ramesh D, et al. Blood pressure control and acceptability of perindopril and its fixed dose combinations with amlodipine or indapamide in younger patients with hypertension. Indian Heart J 2014;66:635-9
   PubMedGoogle Scholar
• Nagy VL. Twenty-four-hour ambulatory blood pressure reduction with a perindopril/amlodipine fixed-dose combination. Clin Drug Invest 2013;33:469-76
   PubMed Web of Science ®Google Scholar
• Ruilope L, Schaefer A. The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: A randomized, double-blind trial in patients with hypertension. Adv Ther 2013;30:1086-99
   PubMed Web of Science ®Google Scholar
• Mancia G, Asmar R, Amodeo C, et al. Comparison of single-pill strategies first line in hypertension: Perindopril/amlodipine versus valsartan/amlodipine. J Hypertens 2015;33:401-11
   PubMed Web of Science ®Google Scholar
• Laurent S, Parati G, Chazova I, et al. Randomized evaluation of a novel, fixed-dose combination of perindopril 3.5 mg/amlodipine 2.5 mg as a first-step treatment in hypertension. J Hypertens 2015;33:653-62
   PubMed Web of Science ®Google Scholar
• Elliott WJ, Whitmore J, Feldstein JD, Bakris GL. Efficacy and safety of perindopril arginine + amlodipine in hypertension. J Am Soc Hypertens 2015;9:266-74
   PubMed Web of Science ®Google Scholar
• Makani H, Bangalore S, Romero J, et al. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med 2011;124:128-35
   PubMed Web of Science ®Google Scholar
• Elliott WJ. An ACE-inhibitor may prevent amlodipine-associated pedal edema more than an angiotensin receptor blocker or aliskiren [abstract]. J Hypertens 2014;32(e-Suppl 1):e592
   Google Scholar
• Chrysant SG, Sugimoto DH, Lefkowitz M, et al. The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy. Blood Press Suppl 2007;1:10-17
   PubMedGoogle Scholar
• Jamerson KA Nwose O, Jean-Louis L, et al. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004;17:495-501
   PubMed Web of Science ®Google Scholar
• Miranda RD, Mion DJr, Rocha JC, et al. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: The Assessment of combination Therapy of Amlodipine/Ramipril (ATAR) study. Clin Ther 2008;30:1618-28
   PubMed Web of Science ®Google Scholar
• Izzo JLJr, Purkayastha D, Hall D, Hilkert RJ. Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension. J Hum Hypertens 2010;24:403-9
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kumar S, Messerli FH. Angiotensin-converting enzyme inhibitor associated cough: Deceptive information from the Physicians’ Desk Reference. Am J Med 2010;123:1016-30
   PubMed Web of Science ®Google Scholar
• David D, Jallad N, Germino FW, et al. A comparison of the cough profile of fosinopril and enalapril in hypertensive patients with a history of ACE inhibitor-associated cough. Am J Ther 1995;2:806-13
   PubMedGoogle Scholar
• Lv Y, Zou Z, Chen GM, et al. Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: A meta-analysis of randomized controlled trials. Blood Press Monit 2010;15:195-204
   PubMed Web of Science ®Google Scholar
• Prestalia®–Another Combination for Hypertension. Med Letter 2015;67:103-4
   Google Scholar
• Taylor AL, Ziesche S, Yancy C, et al. for the African American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-57
   PubMed Web of Science ®Google Scholar